Published in Trials on April 26, 2006
The Key Role of the Blood Supply to Bone. Bone Res (2013) 0.83
Organic nitrate maintains bone marrow blood perfusion in ovariectomized female rats: a dynamic, contrast-enhanced magnetic resonance imaging (MRI) study. Pharmaceutics (2012) 0.79
Nitrates and bone turnover (NABT) - trial to select the best nitrate preparation: study protocol for a randomized controlled trial. Trials (2013) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Epidemiology and outcomes of osteoporotic fractures. Lancet (2002) 13.09
Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med (1995) 13.01
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ (2002) 9.89
Surrogate end points in clinical trials: are we being misled? Ann Intern Med (1996) 9.81
Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev (1985) 7.40
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med (2003) 7.25
World-wide projections for hip fracture. Osteoporos Int (1997) 6.83
Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med (2004) 6.42
Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev (2002) 6.38
A reduced dietary questionnaire: development and validation. Epidemiology (1990) 5.41
Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care (1999) 4.35
Clinical use of bone densitometry: scientific review. JAMA (2002) 3.73
Peak bone mass. Osteoporos Int (2000) 3.49
Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet (1996) 3.18
Intention to treat--who should use ITT? Br J Cancer (1993) 2.74
Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res (1996) 2.47
Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med (2000) 2.46
Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res (2000) 2.27
Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab (2002) 2.15
The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int (2000) 2.14
Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc (2002) 1.97
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res (2003) 1.96
Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res (1998) 1.85
Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA (2000) 1.79
Evaluation of two food frequency methods of measuring dietary calcium intake. Am J Epidemiol (1987) 1.73
Design of the Fracture Intervention Trial. Osteoporos Int (1993) 1.53
Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc Natl Acad Sci U S A (1991) 1.50
Nitric oxide: a cytokine-induced regulator of bone resorption. J Bone Miner Res (1995) 1.37
Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int (2000) 1.36
Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies. Am J Med (1995) 1.35
Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int (2000) 1.28
Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase. Proc Natl Acad Sci U S A (1994) 1.23
Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Proc Natl Acad Sci U S A (1995) 1.21
Clinical use of bone densitometry: clinical applications. JAMA (2002) 1.19
Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res (2004) 1.16
Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int (2000) 1.12
Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone (1996) 1.11
Calcium for prevention of osteoporotic fractures in postmenopausal women. J Bone Miner Res (1997) 1.10
Nitric oxide response to shear stress by human bone cell cultures is endothelial nitric oxide synthase dependent. Biochem Biophys Res Commun (1998) 1.08
Role of nitric oxide and prostaglandins in mechanically induced bone formation. J Bone Miner Res (1998) 1.05
Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial. J Bone Miner Res (2004) 1.05
Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res (1998) 1.04
Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption. J Clin Invest (1994) 1.04
The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med (1990) 1.00
Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity. J Bone Miner Res (1997) 1.00
Biotransformation to nitric oxide of organic nitrates in comparison to other nitrovasodilators. Eur Heart J (1993) 0.98
First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. Eur J Clin Pharmacol (1981) 0.98
The value of biochemical markers of bone turnover in osteoporosis. J Rheumatol (1997) 0.93
In vivo assessment of trabecular bone structure at the distal radius from high-resolution computed tomography images. Phys Med Biol (1996) 0.93
Prevention of corticosteroid-induced bone loss with nitric oxide donor nitroglycerin in male rats. Bone (1997) 0.92
The Michael Mason Prize Essay 1997. Nitric oxide and bone: what a gas! Br J Rheumatol (1997) 0.91
Rates of bone loss in normal women: evidence of accelerated trabecular bone loss after the menopause. Eur J Clin Invest (1988) 0.91
Nitric oxide and its role in orthopaedic disease. Clin Orthop Relat Res (1995) 0.90
Nitric oxide is a regulator of bone remodelling. J Pharm Pharmacol (1997) 0.90
Nitric oxide and bone. J Bone Miner Res (1996) 0.90
Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: a human pilot clinical study. J Bone Miner Res (2000) 0.90
Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. Cardiovasc Drugs Ther (1997) 0.88
In vivo measurement of apparent trabecular bone structure of the radius in women with low bone density discriminates patients with recent wrist fracture from those without fracture. J Clin Densitom (2003) 0.88
Choosing the most appropriate treatment for stable angina. Safety considerations. Drug Saf (1998) 0.86
Headache characteristics during the development of tolerance to nitrates: pathophysiological implications. Cephalalgia (2000) 0.85
Post-menopausal osteoporosis. Best Pract Res Clin Obstet Gynaecol (2002) 0.84
Detection of adverse drug reactions in a clinical trial using two types of questioning. Clin Ther (1981) 0.82
Bone cell function, regulation, and communication: a role for nitric oxide. J Cell Biochem (1995) 0.81
Short and long-acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther (1994) 0.81
The role of bone turnover markers and risk factors in the assessment of osteoporosis and fracture risk. Baillieres Best Pract Res Clin Endocrinol Metab (2000) 0.80
Cultured osteoblast synthesize nitric oxide in response to cytokines and lipopolysaccharide. Kobe J Med Sci (1994) 0.79
Pharmacokinetics of nitroglycerin and long-acting nitrate esters. Am J Med (1983) 0.79
Pharmacokinetics of organic nitrates in man: an overview. Eur Heart J (1988) 0.78
Fracture and the risk of coronary events in women with heart disease. Am J Med (2003) 0.78
Effect of nitroglycerin ointment placement on the severity of headache and flushing in patients with cardiac disease. Heart Lung (1988) 0.78
Hormone replacement therapy improves distal radius bone structure by endocortical mineral deposition. Can J Physiol Pharmacol (2003) 0.77
Effect of nitroglycerin ointment placement on headache and flushing in healthy subjects. Int J Nurs Stud (1991) 0.77
Ointments and transdermal nitroglycerin patches for stable angina pectoris. Cardiovasc Drugs Ther (1994) 0.76
Nitrates for unstable angina. Cardiovasc Drugs Ther (1994) 0.76
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Ultrasonography versus computed tomography for suspected nephrolithiasis. N Engl J Med (2014) 11.30
Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet (2009) 6.66
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med (2008) 5.14
High-trauma fractures and low bone mineral density in older women and men. JAMA (2007) 5.00
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med (2008) 4.81
BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res (2003) 4.64
Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med (2011) 4.28
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
A comparison of prediction models for fractures in older women: is more better? Arch Intern Med (2009) 3.37
Bone mineral density and the risk of incident nonspinal fractures in black and white women. JAMA (2005) 3.30
Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med (2007) 3.27
Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab (2006) 3.15
Long-term risk of incident vertebral fractures. JAMA (2007) 3.15
Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J Am Soc Nephrol (2005) 3.14
A comparison of frailty indexes for the prediction of falls, disability, fractures, and mortality in older men. J Am Geriatr Soc (2009) 3.09
Fetuin-A and incident diabetes mellitus in older persons. JAMA (2008) 2.92
Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res (2012) 2.85
Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell (2009) 2.79
Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care (2002) 2.72
Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med (2008) 2.66
Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA (2003) 2.62
Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA (2007) 2.62
Informed Consent. N Engl J Med (2017) 2.56
Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol (2005) 2.55
Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat (2005) 2.53
Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res (2005) 2.49
Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev (2002) 2.49
Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann Neurol (2011) 2.46
Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med (2008) 2.44
Relationship of changes in physical activity and mortality among older women. JAMA (2003) 2.42
Population structure, admixture, and aging-related phenotypes in African American adults: the Cardiovascular Health Study. Am J Hum Genet (2005) 2.41
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res (2012) 2.34
Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc (2011) 2.34
Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res (2010) 2.29
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer (2011) 2.20
Prediction of incident hip fracture risk by femur geometry variables measured by hip structural analysis in the study of osteoporotic fractures. J Bone Miner Res (2008) 2.18
Volume of mammographic density and risk of breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 2.18
Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum (2005) 2.16
Do muscle mass, muscle density, strength, and physical function similarly influence risk of hospitalization in older adults? J Am Geriatr Soc (2009) 2.04
Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci (2009) 2.01
Alendronate and atrial fibrillation. N Engl J Med (2007) 2.00
The genetics of human longevity. Am J Med (2004) 1.97
Circulating 25-hydroxyvitamin D levels and frailty status in older women. J Clin Endocrinol Metab (2010) 1.93
Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res (2007) 1.93
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res (2012) 1.92
Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res (2007) 1.88
Factors associated with kyphosis progression in older women: 15 years' experience in the study of osteoporotic fractures. J Bone Miner Res (2013) 1.84
Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc (2004) 1.84
Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res (2007) 1.79
Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? N Engl J Med (2012) 1.79
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res (2012) 1.78
Comparison of methods to measure low serum estradiol levels in postmenopausal women. J Clin Endocrinol Metab (2006) 1.76
Finite element analysis of the proximal femur and hip fracture risk in older men. J Bone Miner Res (2009) 1.73
Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med (2006) 1.72
Intentional and unintentional weight loss increase bone loss and hip fracture risk in older women. J Am Geriatr Soc (2003) 1.72
The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. J Bone Miner Res (2011) 1.70
Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res (2006) 1.65
Hip fracture and increased short-term but not long-term mortality in healthy older women. Arch Intern Med (2011) 1.64
Nulliparity and fracture risk in older women: the study of osteoporotic fractures. J Bone Miner Res (2003) 1.62
Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry (2005) 1.62
Sex hormone levels and risk of breast cancer with estrogen plus progestin. J Natl Cancer Inst (2013) 1.60
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab (2013) 1.60
Single x-ray absorptiometry method for the quantitative mammographic measure of fibroglandular tissue volume. Med Phys (2009) 1.58
Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines. J Bone Miner Res (2009) 1.58
Retracted Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial. JAMA (2011) 1.57
Validation of an armband to measure daily energy expenditure in older adults. J Gerontol A Biol Sci Med Sci (2011) 1.56
Proximal femoral structure and the prediction of hip fracture in men: a large prospective study using QCT. J Bone Miner Res (2008) 1.55
Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am (2012) 1.54
Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ (2008) 1.54
Low serum vitamin B-12 levels are associated with increased hip bone loss in older women: a prospective study. J Clin Endocrinol Metab (2004) 1.54
Renal function and heart failure risk in older black and white individuals: the Health, Aging, and Body Composition Study. Arch Intern Med (2006) 1.54
Cystatin C and risk of hip fractures in older women. J Bone Miner Res (2013) 1.54
Balloon kyphoplasty for the treatment of acute vertebral compression fractures: 2-year results from a randomized trial. J Bone Miner Res (2011) 1.52
Effect of raloxifene on urinary incontinence: a randomized controlled trial. Obstet Gynecol (2004) 1.51
Adipocytokines attenuate the association between visceral adiposity and diabetes in older adults. Diabetes Care (2004) 1.50
Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1. Arch Intern Med (2006) 1.49
Kidney function and cognitive performance and decline in older men. J Am Geriatr Soc (2008) 1.48
Telomere length and cognitive function in community-dwelling elders: findings from the Health ABC Study. Neurobiol Aging (2009) 1.46
Physical performance and risk of hip fractures in older men. J Bone Miner Res (2008) 1.45
Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women. Menopause (2007) 1.44
Skeletal muscle mitochondrial energetics are associated with maximal aerobic capacity and walking speed in older adults. J Gerontol A Biol Sci Med Sci (2012) 1.44
Serum 25-hydroxyvitamin D levels and rate of hip bone loss in older men. J Clin Endocrinol Metab (2009) 1.44
Self-reported sleep and nap habits and risk of mortality in a large cohort of older women. J Am Geriatr Soc (2009) 1.43
Actigraphy-measured sleep characteristics and risk of falls in older women. Arch Intern Med (2008) 1.42
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol (2002) 1.42
Filtering FRAX. Osteoporos Int (2010) 1.40
Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt) (2003) 1.39
Primary sclerosing cholangitis: summary of a workshop. Hepatology (2006) 1.38
Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab (2009) 1.38
A new framework for describing and quantifying the gap between proof and practice. Med Care (2003) 1.38
Hyperkyphosis predicts mortality independent of vertebral osteoporosis in older women. Ann Intern Med (2009) 1.38
Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures. J Bone Miner Res (2004) 1.38